【LWBP NEWS】Next-generation of Oral JAK1 Selective Inhibitor LW402 Demonstrates Surprising Efficacy in Rheumatoid Arthritis Phase II Clinical Study Results Recently, LW402, a next-generation oral JAK1 selective inhibitor independently developed by LWBP, has completed all patient dosing and data collection in a Phase II clinical study on rheumatoid arthri... Company News Apr 2, 2024
【LWBP NEWS】LW402, a next-generation oral JAK1-selective inhibitor independently developed by LWBP, was approved for clinical studies in vitiligo Recently, LW402 was approved to conduct clinical studies in vitiligo. LW402 is a next-generation highly selective JAK1 inhibitor independently developed by LWBP. The safety and efficacy of LW402 have ... Company News Mar 8, 2024
【LWBP NEWS】LWBP Releases Updated Data on LW231, a Self-Developed Novel Hepatitis B Drug, at AASLD2023-The Liver Meeting Recently, Shangha i Longwood Biop harmaceutical s (LWBP) shared the latest research poster of LW231, a self-developed novel Hepatitis B drug, at AASLD2023-The Liver Meeting held in Boston, USA. As the... Company News Nov 16, 2023
【LWBP NEWS】LWBP was awarded "Grand Neo Bay 2023 - Top 10 Innovative and Entrepreneurial Enterprise - Biomedical Sector" On 30th October, the "Award Ceremony for Grand Neo Bay 2023 - Top 10 Innovative and Entrepreneurial Enterprise" was held at the Grand Neo Bay Science and Innovation Building, hosted by the Minhang Dis... Company News Nov 1, 2023
【LWBP NEWS】LWBP Wins the First Prize of the Fifth Lianyungang "Huaguo Mountain Talents" Innovation and Entrepreneurship Competition 2023 Recently, LWBP was invited to participate in the fifth "Huaguo Mountain Talents" Innovation and Entrepreneurship Competition Final held in Lianyungang, Jiangsu. The final competition took on-site road... Company News Sep 2, 2023
【LWBP NEWS】Second Generation JAK1 Selective Inhibitor LW402 Clinical Phase II Trial Demonstrates Positive Progress Recently, LWBP announced that its new generation JAK1-selective inhibitor LW402, which was independently developed by LWBP, has been initiated to be clinically administered to the first group of patie... Company News Aug 19, 2023
Phase II clinical study of a new generation oral small molecule JAK1-selective inhibitor for multiple indications successfully initiated Recently, the clinical phase II study of LW402, a novel oral highly JAK1-selective inhibitor developed by LWBP, for the treatment of autoimmune diseases such as atopic dermatitis(AD) and rheumatoid ar... Company News Jun 5, 2023
New Class I Bifunctional Hepatitis B Drug Makes Clinical Positive progression Recently, the Bifunctional hepatitis B drug-LW 231, self-developed by Shanghai Longwood Biopharmaceuticals Co., LTD., has made positive progress in the phase I clinical study. Hepatitis B virus (HBV) ... Company News Jun 5, 2023
Longwood Biopharmaceuticals initiates clinical phase II study of LW402, a next-generation JAK1 inhibitor Longwood Biopharmaceuticals initiates clinical phase II study of LW402, a next-generation JAK1 inhibitor Recently, Longwood Biopharmaceuticals announced the initiation of a Phase II clinical study of ... Company News Mar 30, 2023
LongwoodPharmaceuticals Deeply Committed to the Pharmaceutical Industry, Contributing to the Health of China 时间：2021年08月02日 14:31 栏目：广特播报 作者：广通社 Science and technology self-reliance and self-improvement is the strategic support of national development, adhere to scientific and technological innovation is dri... Company News Mar 30, 2023